EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dose Escalation of Oropharyngeal Cancer: Long-Time Follow-Up and Side Effects

Anna Embring iD, Eva Onjukka iD, Claes Mercke, Ingmar Lax, Anders Berglund, Signe Friesland iD

Cancers · 30.04.2023 · 15 (9) · 2580

DOI: 10.3390/cancers15092580 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 30.04.2023. Verfasst von Anna Embring und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Karolinska University Hospital, 17176 Stockholm, Sweden. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: King Gustaf V Jubilee Fund (Stockholm, Sweden).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Previous studies on dose-escalated radiotherapy in head and neck cancer have shown mixed results, and it is not established which patients would benefit from dose escalation. Further, while dose escalation does not appear to increase late toxicity, this needs to be confirmed with longer follow-up. In this study, we analysed treatment outcome and toxicity in 215 patients with oropharyngeal cancer treated with dose-escalated radiotherapy (>72 Gy, EQD2, α/β = 10 Gy, boost by brachytherapy or simultaneous integrated boost) and a matched cohort of 215 patients treated with standard dose external-beam radiotherapy (68 Gy) between 2011 and 2018 at our institution. The 5-year overall survival (OS) was 77.8% (72.4–83.6) and 73.7% (67.8–80.1) in the dose-escalated and standard dose group, respectively (p = 0.24). Median follow-up was 78.1 (49.2–98.4) and 60.2 (38.9–89.4) months in the dose-escalated and standard dose groups, respectively. Grade ≥3 osteoradionecrosis (ORN) and late dysphagia were more common in the dose-escalated group compared to the standard dose group, with 19 (8.8%) vs. 4 (1.9%) patients developing grade ≥3 ORN (p = 0.001), and 39 (18.1%) vs. 21 (9.8%) patients developing grade ≥3 dysphagia (p = 0.01). No predictive factors to help select patients for dose-escalated radiotherapy were found. However, the remarkably good OS in the dose-escalated cohort, despite a predominance of advanced tumour stages, encourages further attempts to identify such factors.

Schlagwörter

Stichwörter der Autor:innen

dose escalationdysphagiahead and neck canceroropharyngeal cancerosteoradionecrosisradiotherapyside effects

Autor:innen und Institutionen

  • Department of Oncology, Karolinska University Hospital, 17176 Stockholm, Sweden.
  • Karolinska Institute, Department of Oncology-Pathology, 17176 Stockholm, Sweden.
  • Department of Medical Radiation Physics and Nuclear Medicine, Karolinska University Hospital, 17176 Stockholm, Sweden.
  • Epistat Epidemiology and Statistics Consulting, 75655 Uppsala, Sweden.

ORCID-Profile: Anna Embring, Eva Onjukka, Signe Friesland

Förderung

  • King Gustaf V Jubilee Fund (Stockholm, Sweden)

Zitieren

APA

Embring, A., Onjukka, E., Mercke, C., Lax, I., Berglund, A., & Friesland, S. (2023). Dose Escalation of Oropharyngeal Cancer: Long-Time Follow-Up and Side Effects. Cancers, 15(9), 2580. https://doi.org/10.3390/cancers15092580

Vancouver

Embring A, Onjukka E, Mercke C, Lax I, Berglund A, Friesland S. Dose Escalation of Oropharyngeal Cancer: Long-Time Follow-Up and Side Effects. Cancers. 2023;15(9):2580. doi:10.3390/cancers15092580

BibTeX
@article{Embring2023,
  author = {Embring, Anna and Onjukka, Eva and Mercke, Claes and Lax, Ingmar and Berglund, Anders and Friesland, Signe},
  title = {Dose Escalation of Oropharyngeal Cancer: Long-Time Follow-Up and Side Effects},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {9},
  pages = {2580},
  doi = {10.3390/cancers15092580}
}
Kostenlos starten →